S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
NASDAQ:ABUS

Arbutus Biopharma Stock Forecast, Price & News

$2.71
+0.02 (+0.74%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.61
$2.79
50-Day Range
$2.68
$4.61
52-Week Range
$2.41
$6.50
Volume
2.33 million shs
Average Volume
3.05 million shs
Market Capitalization
$366.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.66
30 days | 90 days | 365 days | Advanced Chart
Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Arbutus Biopharma logo

About Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Headlines

Arbutus Biopharma outlines milestones for 2022
January 24, 2022 |  seekingalpha.com
Why Arbutus Biopharma Shares Are Rising
December 13, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABUS
Employees
77
Year Founded
1992

Sales & Book Value

Annual Sales
$6.91 million
Book Value
($0.53) per share

Profitability

Net Income
$-63.74 million
Net Margins
-707.79%
Pretax Margin
-707.79%

Debt

Price-To-Earnings

Miscellaneous

Free Float
124,989,000
Market Cap
$366.58 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/26/2022
Next Earnings (Estimated)
3/03/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

709th out of 1,416 stocks

Pharmaceutical Preparations Industry

342nd out of 684 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma
or view top-rated stocks.

How has Arbutus Biopharma's stock price been impacted by COVID-19?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ABUS stock has increased by 5.0% and is now trading at $2.71.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a decline in short interest in December. As of December 31st, there was short interest totaling 4,550,000 shares, a decline of 43.5% from the December 15th total of 8,060,000 shares. Based on an average daily trading volume, of 9,480,000 shares, the days-to-cover ratio is presently 0.5 days.
View Arbutus Biopharma's Short Interest
.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Arbutus Biopharma
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, hitting analysts' consensus estimates of ($0.24). The biopharmaceutical company earned $3.34 million during the quarter, compared to analyst estimates of $2.36 million. During the same quarter in the previous year, the company earned ($0.27) earnings per share.
View Arbutus Biopharma's earnings history
.

What price target have analysts set for ABUS?

5 brokerages have issued 12-month price objectives for Arbutus Biopharma's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Arbutus Biopharma's share price to reach $6.90 in the next year. This suggests a possible upside of 154.6% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:
  • William H. Collier, President, Chief Executive Officer & Director
  • David C. Hastings, Chief Financial & Accounting Officer
  • Michael J. Sofia, Chief Scientific Officer
  • Elizabeth Howard, Secretary, Chief Compliance Officer & EVP
  • Michael J. McElhaugh, Chief Business Officer

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%).
View institutional ownership trends for Arbutus Biopharma
.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Arbutus Biopharma
or or view top insider-buying stocks.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.71.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $366.58 million and generates $6.91 million in revenue each year. The biopharmaceutical company earns $-63.74 million in net income (profit) each year or ($0.91) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 77 workers across the globe.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

Where are Arbutus Biopharma's headquarters?

Arbutus Biopharma is headquartered at 701 VETERANS CIRCLE, WARMINSTER PA, 18974.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at [email protected], or via fax at 604-419-3201.


This page was last updated on 1/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.